Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to ...

Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon Biologics to consolidate its biosimilars and generics drug businesses.

BANGALORE, Aug 23 (Reuters) - India's top listed biotechnology firm Biocon Ltd expects revenue growth of 15 percent over the next two years each, while seeking partnerships with global drugmakers for ...

Biocon shares jump 8% post Q4 results. Is the Street happy? Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings ...

BENGALURU, India and BRIDGEWATER, N.J., Oct. 1, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON) ...

MUMBAI, April 5 (Reuters) - Biocon , India's top listed biotechnology firm, said it had entered into an agreement to buy the remaining 49 percent stake in its biopharmaceuticals unit from joint ...

A survey conducted by Biocon Foundation in partnership with IISc has revealed an improvement in quality of life and health ...